CAS:254750-02-2   (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
CAS:254750-02-2   (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
+
  • CAS:254750-02-2   (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
  • CAS:254750-02-2   (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

CAS:254750-02-2 (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid

NAME:(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid CAS:254750-02-2 MF:C26H27F4N3O7 MW:569.51 PURITY:98%

Categories:

Material Chemistry

Product introduction

NAME (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
CAS 254750-02-2
MF C26H27F4N3O7
MW 569.51
DENSITY 1.386
STORAGE -20°C

Description
Emricasan, also known as IDN-6556 and PF-03491390, is a potential drug that was invented in 1998 by Idun Pharmaceuticals  . It was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010 . Emricasan is the first caspase inhibitor tested in humans and has received orphan drug status by the FDA . It is developed in such a way that it protects liver cells from excessive apoptosis . It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis .
 

Key words:

Related Products

Related Products

Inquiry

SUBMIT